|
Sign In to gain access to subscriptions and/or personal tools.
|
Profiles of Cytokines (TNF and IL-6) and Acute Phase Proteins (CRP and 1AG) related to the Disease Course in Patients with Systemic Lupus Erythematosus
C. Meijer
Department of Rheumatology, Dr Daniel den Hoed Clinic, PO Box 5201, 3008 AE Rotterdam
V. Huysen
Departrnent of Autoimmune Diseases, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
R.T.J. Smeenk
Departrnent of Autoimmune Diseases, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands
A.J.G. Swaak
Department of Rheumatology, Dr Daniel den Hoed Clinic, PO Box 5201, 3008 AE Rotterdam
Tumor necrosis factor (TNF ) and interleukin-6 (IL-6) play a main role in inducing acute phase protein production by hepatocytes. This study describes the serum levels of TNF and IL-6 in relation to serum levels of C-reactive protein (CRP) and 1-acid glycoprotein ( 1AG) in three systemic lupus erythematosus (SLE) patients. Disease courses of these patients were divided in a total of 19 clinical periods, according to the clinical symptoms and interleukine profiles. Significantly elevated TNF levels were found in all but three of the defined periods, without being associated with disease activity. In only four of the defined periods elevated TNF were observed combined with elevated IL-6 and CRP levels. Two of these periods coincided with minor symptoms of SLE, one with an exacerbation and the other one with a systemic infection while SLE activity was low. All other periods showed varying combinations of elevated TNF and/or IL-6 levels being followed or not by elevated CRP levels. Significantly raised 1AG levels were measured in all clinical periods. In most of the observed periods a dissociation was found between TNF and IL-6 and also between the different cytokine (TNF and IL-6) levels and acute phase protein (CRP and 1AG) levels. These data could not be explained by differences in disease course or influences of medication. We conclude that more factors other than TNF and IL-6 must play a role in the regulatory pathway of the acute phase response in SLE. These data are also highly suggestive of an imbalance between TNF, IL-6 and the acute phase reaction.
Key Words: TNF IL-6 CRP 1AG
Lupus, Vol. 2, No. 6,
359-365 (1993)
DOI: 10.1177/096120339300200605

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Usmani and M. Goodfield
Efalizumab in the Treatment of Discoid Lupus Erythematosus
Arch Dermatol,
July 1, 2007;
143(7):
873 - 877.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Steinbach, F. Henke, B. Krause, B. Thiele, G.-R. Burmester, and F. Hiepe
Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility
Ann Rheum Dis,
April 1, 2000;
59(4):
283 - 288.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Gordon and P. Emery
Cytokines and the Acute Phase Response in SLE
Lupus,
December 1, 1993;
2(6):
345 - 347.
[PDF]
|
 |
|
|
|